Cogstate (CGS) Q1 2027 TU earnings summary

Executive summary

• Q1 FY27 sales contracts executed totaled $25.13m; five Phase 3 bipolar or depression trials across two customers contributed over 80% of quarter contract value.

• Channel partnerships helped secure competitive programs by letting sponsors use preferred clinical technology providers alongside specialist endpoint-quality services.

Financial highlights

• Contracted revenue at 30 Sep 2026 was $143.7m, up 41% YoY from $101.8m.

• Contracted revenue was $31.7m for 1H27, up 38% YoY; $56.8m for FY27, up 45%; and $86.9m for FY28–FY33, up 39%.

Outlook and guidance

• Contracted FY27 revenue rose to $56.8m at 30 Sep 2026 from $48.3m at 30 Jun; Q1 contracts contributed $8.4m, a 34% in-year revenue yield.

• Contracted FY28 revenue increased to $39.7m from $31.4m QoQ, strengthening longer-term revenue coverage.